Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol

PLoS One. 2016 Mar 7;11(3):e0149615. doi: 10.1371/journal.pone.0149615. eCollection 2016.

Abstract

Study question: What is the threshold for the prediction of moderate to severe or severe ovarian hyperstimulation syndrome (OHSS) based on the number of growing follicles ≥ 11 mm and/or estradiol (E2) levels?

Summary answer: The optimal threshold of follicles ≥11 mm on the day of hCG to identify those at risk was 19 for both moderate to severe OHSS and for severe OHSS. Estradiol (E2) levels were less prognostic of OHSS than the number of follicles ≥ 11 mm.

What is known already: In comparison to long gonadotropin-releasing hormone (GnRH) agonist protocols, the risk of severe OHSS is reduced by approximately 50% in a GnRH antagonist protocol for ovarian stimulation prior to in vitro fertilisation (IVF), while the two protocols provide equal chances of pregnancy per initiated cycle. Nevertheless, moderate to severe OHSS may still occur in GnRH antagonist protocols if human chorionic gonadotropin (hCG) is administered to trigger final oocyte maturation, especially in high responder patients. Severe OHSS following hCG trigger may occur with an incidence of 1-2% in a relatively young (aged 18 to 36 years) IVF population treated in a GnRH-antagonist protocol.

Study design, size, duration: From the Engage, Ensure and Trust trials, in total, 2,433 women who received hCG for oocyte maturation and for whom the number of follicles ≥ 11 mm and the level of E2 on the day of hCG administration were known were included in the analyses.

Participants/materials, setting, methods: The threshold for OHSS prediction of moderate and severe OHSS was assessed in women treated with corifollitropin alfa or daily recombinant follicle stimulation hormone (rFSH) in a gonadotropin-releasing hormone (GnRH)-antagonist protocol. Receiver operating characteristics curve analyses for moderate to severe OHSS and severe OHSS were performed on the combined dataset and the sensitivity and specificity for the optimal threshold of number of follicles ≥ 11 mm, E2 levels on the day of (hCG), and a combination of both, were determined.

Main results and the role of chance: The optimal threshold of follicles ≥ 11 mm on the day of hCG to identify those at risk of moderate to severe OHSS was 19 (sensitivity and specificity 62.3% and 75.6%, respectively) and for severe OHSS was also 19 (sensitivity and specificity 74.3% and 75.3%, respectively). The positive and negative predictive values were 6.9% and 98.6%, respectively, for moderate to severe OHSS, and 4.2% and 99.5% for severe OHSS.

Limitations, reasons for caution: This was a retrospective analysis of combined data from three trials following ovarian stimulation with two different gonadotropins.

Wider implications of the findings: For patients with 19 follicles or more ≥11 mm on the day of hCG, measures to prevent the development of OHSS should be considered. Secondary preventive measures include cycle cancellation or coasting, use of a GnRH agonist to trigger final oocyte maturation in place of hCG and a freeze all strategy.

Trial registration: ClinicalTrials.gov NCT00702845 NCT00696800 NCT00696878.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Chorionic Gonadotropin / adverse effects*
  • Chorionic Gonadotropin / pharmacology*
  • Clinical Trials as Topic
  • Estradiol / metabolism
  • Female
  • Follicle Stimulating Hormone, Human / adverse effects*
  • Follicle Stimulating Hormone, Human / pharmacology*
  • Gonadotropin-Releasing Hormone / antagonists & inhibitors*
  • Hormone Antagonists / adverse effects
  • Hormone Antagonists / pharmacology
  • Humans
  • Organ Size / drug effects
  • Ovarian Follicle / drug effects
  • Ovarian Follicle / growth & development
  • Ovarian Hyperstimulation Syndrome / chemically induced*
  • Ovarian Hyperstimulation Syndrome / diagnosis*
  • Ovarian Hyperstimulation Syndrome / metabolism
  • Ovarian Hyperstimulation Syndrome / pathology
  • Ovulation Induction / adverse effects
  • Pregnancy
  • Prognosis
  • Retrospective Studies
  • Young Adult

Substances

  • Chorionic Gonadotropin
  • Follicle Stimulating Hormone, Human
  • Hormone Antagonists
  • follicle stimulating hormone, human, with HCG C-terminal peptide
  • Gonadotropin-Releasing Hormone
  • Estradiol

Associated data

  • ClinicalTrials.gov/NCT00696800
  • ClinicalTrials.gov/NCT00696878
  • ClinicalTrials.gov/NCT00702845

Grants and funding

Financial support for this study was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ. The funder provided financial support in the form of salaries for authors PJMV, DG, KG and BJS, and research materials, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section of the paper.